Announcements

    Drinks

      THURSDAY, 25/01/2018 - Scope Ratings AG
      Download PDF

      Sanofi ratings unaffected by Bioverativ acquisition

      Scope believes that the recently announced USD 11.6 bn acquisition of US-based biotech company Bioverativ is not a challenge for Sanofi’s credit rating.

      While the transaction, which is still pending regulatory approval, is fully funded by a combination of cash and additional debt, its likely negative impact on Sanofi’s financial risk profile is of insignificant relevance in the context of the ratings. This is not to say credit metrics will not deteriorate in 2018 compared to the previous year, but Scope believes that the likely deterioration will not be strong enough to justify a negative rating action.

      Scope had stated in its last outlook statement that the rating reflects Sanofi being able to maintain the following Scope-adjusted credit metrics: funds from operations to debt of 60%, and free operating cash flow to debt of at least 40%. The agency does not believe that the acquisition of Bioverativ is likely to endanger these thresholds meaningfully and can thus maintain the ratings.

      Related news

      Show all
      Real Estate Insight - April 2024

      12/4/2024 Research

      Real Estate Insight - April 2024

      Scope withdraws ratings on MG RE Invest S.A. for lack of data and information.

      11/4/2024 Rating announcement

      Scope withdraws ratings on MG RE Invest S.A. for lack of data ...

      Scope downgrades SBB’s senior unsecured debt to CCC, maintains under review

      10/4/2024 Rating announcement

      Scope downgrades SBB’s senior unsecured debt to CCC, ...

      Germany’s auto parts sector: defaults point to consolidation in cyclical downturn rather than crisis

      10/4/2024 Research

      Germany’s auto parts sector: defaults point to consolidation ...

      Scope affirms Lyse's A-/Stable issuer rating

      8/4/2024 Rating announcement

      Scope affirms Lyse's A-/Stable issuer rating

      DKR’s issuer rating downgraded to C from CC, rating maintained under review for a developing outcome

      5/4/2024 Rating announcement

      DKR’s issuer rating downgraded to C from CC, rating ...